Amneal Pharmaceuticals, Inc.
AMRX- 1M
- +6.5%
Amneal Pharmaceuticals, Inc. in brief
Amneal Pharmaceuticals, Inc. is a listed company in the Pharmaceutical industry, based in New Jersey, USA. Its market value was $6.7 B on 16 October 2026, which makes it the 2,900th largest listed company in the world and the 885th largest in the USA on this site. In the year to December 2025 it had sales of $3.0 B and a net profit of $72 M, about 2 cents of profit for every dollar of sales. It employs about 8,500 people and Chintu Patel is its chief executive. Its largest product and service lines by sales in 2025 were Subtotal dosage forms (57%), Oral solid (24%) and Subtotal therapeutic classes (17%). Its shares trade under the symbol AMRX (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Amneal Pharmaceuticals, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔· approximateInitial public offering on NYSE
- •Legal Entity Identifier issuedLEI 549300VV176ZO5WQHZ61 registered.
- ✎Renamed Amneal Pharmaceuticals, Inc.Formerly Atlas Holdings, Inc..
- 📉· approximateDelisted from Nasdaq
- 📈· approximateListed on New York Stock Exchange as AMRX
- 2025
- 💰Record revenue of $3.0 billionFY2025, the highest of the 8 years on record.
- 💰Record net income of $72 millionFY2025, the highest profit of the 3 years on record.
Events of Amneal Pharmaceuticals, Inc. from SEC EDGAR, the company record, the GLEIF LEI register, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,739 (Jan 2020) · #2,509 (Jan 2021) · #2,905 (Jan 2022) · #3,097 (Dec 2022) · #2,143 (Jul 2023) · #1,615 (Jan 2024) · #959 (Aug 2026) · #910 (Sep 2026) · #886 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 50.3×
- Price / sales (TTM)
- 2.1×
- Price / book
- —
- Free cash flow yield
- 4.0%
- Net margin (TTM)
- 4.2%
- Operating margin
- 13.1%
- Return on equity
- —
- Liabilities / assets
- 101.9%
- Net debt
- $2.3B
- Revenue growth
- +8.0%
- R&D / revenue
- 6.2%
- Revenue per employee
- $355 K
- Profit per employee
- $8 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.0B | +8.0% | $394M | $72M | 2.4% |
| Dec 2024 | $2.8B | +16.7% | $249M | $-117M | -4.2% |
| Dec 2023 | $2.4B | +8.2% | $204M | $-84M | -3.5% |
| Dec 2022 | $2.2B | +5.7% | $-95M | $-271M | -12.2% |
| Dec 2021 | $2.1B | +5.1% | $153M | $13M | 0.6% |
| Dec 2020 | $2.0B | +22.5% | $91M | $68M | 3.4% |
| Dec 2019 | $1.6B | -2.2% | $-249M | $-604M | -37.1% |
| Dec 2018 | $1.7B | — | $-20M | $-20M | -1.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $340M | $70M | $270M | $0.22 | — |
| Dec 2024 | $295M | $52M | $243M | $-0.38 | — |
| Dec 2023 | $346M | $43M | $302M | $-0.48 | — |
| Dec 2022 | $65M | $46M | $19M | $-0.86 | — |
| Dec 2021 | $242M | $48M | $194M | $0.07 | — |
| Dec 2020 | $379M | $56M | $323M | $0.61 | — |
| Dec 2019 | $2M | $47M | $-45M | $-2.74 | — |
| Dec 2018 | $250M | $83M | $167M | $-0.16 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $863M (+10.0% on a year earlier), net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
Annual and quarterly reports
Amneal Pharmaceuticals, Inc.'s reports from the last 8 years, from the official filing system. Downloads (Excel financial statements, PDF, the report as filed, or everything as a ZIP) are for Premium subscribers — sign in.
Annual · 8
- Dec 31, 202510-KAnnual reportExcelReportZIP
- Dec 31, 202410-KAnnual reportExcelReportZIP
- Dec 31, 202310-KAnnual reportExcelReportZIP
- Dec 31, 202210-KAnnual reportExcelReportZIP
- Dec 31, 202110-KAnnual reportExcelReportZIP
- Dec 31, 202010-KAnnual reportExcelReportZIP
- Dec 31, 201910-KAnnual reportExcelReportZIP
- Dec 31, 201810-KAnnual reportExcelReportZIP
Quarterly · 23
- Jun 30, 202610-QQuarterly reportExcelReportZIP
- Mar 31, 202610-QQuarterly reportExcelReportZIP
- Sep 30, 202510-QQuarterly reportExcelReportZIP
- Jun 30, 202510-QQuarterly reportExcelReportZIP
- Mar 31, 202510-QQuarterly reportExcelReportZIP
- Sep 30, 202410-QQuarterly reportExcelReportZIP
- Jun 30, 202410-QQuarterly reportExcelReportZIP
- Mar 31, 202410-QQuarterly reportExcelReportZIP
- Sep 30, 202310-QQuarterly reportExcelReportZIP
- Jun 30, 202310-QQuarterly reportExcelReportZIP
- Mar 31, 202310-QQuarterly reportExcelReportZIP
- Sep 30, 202210-QQuarterly reportExcelReportZIP
- Jun 30, 202210-QQuarterly reportExcelReportZIP
- Mar 31, 202210-QQuarterly reportExcelReportZIP
- Sep 30, 202110-QQuarterly reportExcelReportZIP
- Jun 30, 202110-QQuarterly reportExcelReportZIP
- Mar 31, 202110-QQuarterly reportExcelReportZIP
- Sep 30, 202010-QQuarterly reportExcelReportZIP
- Jun 30, 202010-QQuarterly reportExcelReportZIP
- Mar 31, 202010-QQuarterly reportExcelReportZIP
- Sep 30, 201910-QQuarterly reportExcelReportZIP
- Jun 30, 201910-QQuarterly reportExcelReportZIP
- Mar 31, 201910-QQuarterly reportExcelReportZIP
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 3, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 23, 20268-K/ACurrent report (amended)
- Aug 10, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · New financial obligation · Unregistered share sale · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportMaterial agreement
- Jul 31, 20268-KCurrent reportShareholder vote
- Jul 30, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportShareholder vote
- May 7, 20268-KCurrent reportResults of operations
- Apr 22, 20268-KCurrent reportMaterial agreement · Results of operations · Unregistered share sale · Regulation FD disclosure
Official filings of Amneal Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $3.0 B
- Operating income
- $394 M
- Net income
- $72 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $3.7 B
- Total liabilities
- $3.7 B
- Total equity
- $-71 M
As of December-2025
Top 100 institutional investors in Amneal Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 26,877,188 | +315,095 (+1.19%) | 7.71% | $541 M | Nov 13, 2026 |
| 2 | Vanguard Portfolio Management LLC | 12,365,663 | +227,936 (+1.88%) | 3.55% | $249 M | Nov 13, 2026 |
| 3 | TPG GP A, LLC | 12,328,767 | 0 (0.00%) | 3.54% | $248 M | Nov 16, 2026 |
| 4 | Rubric Capital Management LP | 8,536,755 | -1,631,905 (-16.05%) | 2.45% | $172 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 7,987,664 | +277,538 (+3.60%) | 2.29% | $161 M | Nov 13, 2026 |
| 6 | State Street Corp | 7,471,033 | +114,056 (+1.55%) | 2.14% | $150 M | Nov 12, 2026 |
| 7 | Citadel Advisors LLC | 6,993,701 | +5,874,986 (+525.15%) | 2.01% | $141 M | Nov 16, 2026 |
| 8 | Invesco Ltd. | 5,965,042 | +2,463,042 (+70.33%) | 1.71% | $120 M | Nov 12, 2026 |
| 9 | Dimensional Fund Advisors LP | 5,816,123 | +21,860 (+0.38%) | 1.67% | $117 M | Nov 4, 2026 |
| 10 | Geode Capital Management, LLC | 4,568,902 | -570,547 (-11.10%) | 1.31% | $92 M | Nov 6, 2026 |
| 11 | Morgan Stanley | 4,270,159 | +160,131 (+3.90%) | 1.23% | $86 M | Nov 13, 2026 |
| 12 | Allspring Global Investments Holdings, LLC | 3,831,581 | +536,048 (+16.27%) | 1.10% | $77 M | Nov 4, 2026 |
| 13 | Neuberger Berman Group LLC | 3,350,096 | -537,083 (-13.82%) | 0.96% | $67 M | Nov 13, 2026 |
| 14 | Nuveen, LLC | 3,198,986 | -125,889 (-3.79%) | 0.92% | $64 M | Nov 10, 2026 |
| 15 | Goldman Sachs Group Inc | 2,595,553 | -418,408 (-13.88%) | 0.74% | $52 M | Nov 16, 2026 |
| 16 | Charles Schwab Investment Management Inc | 2,478,891 | +331,441 (+15.43%) | 0.71% | $50 M | Nov 16, 2026 |
| 17 | Tri Locum Partners LP | 2,326,733 | New | 0.67% | $47 M | Nov 16, 2026 |
| 18 | Nantahala Capital Management, LLC | 2,115,749 | -2,421,753 (-53.37%) | 0.61% | $43 M | Nov 13, 2026 |
| 19 | Assenagon Asset Management S.A. | 2,026,781 | -2,864,317 (-58.56%) | 0.58% | $41 M | Oct 15, 2026 |
| 20 | Northern Trust Corp | 1,823,873 | -91,022 (-4.75%) | 0.52% | $37 M | Nov 16, 2026 |
| 21 | Ameriprise Financial Inc | 1,552,969 | -28,900 (-1.83%) | 0.45% | $31 M | Nov 16, 2026 |
| 22 | Congress Asset Management Co | 1,524,355 | +741,577 (+94.74%) | 0.44% | $31 M | Oct 6, 2026 |
| 23 | Balyasny Asset Management L.P. | 1,343,165 | +909,033 (+209.39%) | 0.39% | $27 M | Nov 16, 2026 |
| 24 | Acadian Asset Management LLC | 1,296,266 | -353,989 (-21.45%) | 0.37% | $26 M | Nov 9, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 1,228,472 | +59,190 (+5.06%) | 0.35% | $25 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | FMR LLC | 1,209,248 | +384,128 (+46.55%) | 0.35% | $24 M | Nov 10, 2026 |
| 27 | Principal Financial Group Inc | 1,146,813 | +154,996 (+15.63%) | 0.33% | $23 M | Nov 2, 2026 |
| 28 | Public Sector Pension Investment Board | 1,026,235 | +434,400 (+73.40%) | 0.29% | $21 M | Nov 10, 2026 |
| 29 | Bank of New York Mellon Corp | 996,932 | -18,250 (-1.80%) | 0.29% | $20 M | Nov 5, 2026 |
| 30 | First Trust Advisors LP | 955,599 | +341,393 (+55.58%) | 0.27% | $19 M | Nov 12, 2026 |
| 31 | UBS Group AG | 902,453 | +458,053 (+103.07%) | 0.26% | $18 M | Nov 10, 2026 |
| 32 | Raymond James Financial Inc | 874,367 | +97,099 (+12.49%) | 0.25% | $18 M | Nov 12, 2026 |
| 33 | PFM Health Sciences, LP | 822,891 | +342,176 (+71.18%) | 0.24% | $17 M | Nov 16, 2026 |
| 34 | Panagora Asset Management Inc | 790,578 | +346,931 (+78.20%) | 0.23% | $16 M | Nov 12, 2026 |
| 35 | Bank Of America Corp /de/ | 779,565 | -15,972 (-2.01%) | 0.22% | $16 M | Nov 16, 2026 |
| 36 | BNP Paribas Financial Markets | 727,677 | +62,787 (+9.44%) | 0.21% | $15 M | Nov 12, 2026 |
| 37 | Soleus Capital Management, L.P. | 658,000 | New | 0.19% | $13 M | Nov 16, 2026 |
| 38 | Pictet Asset Management Holding SA | 638,040 | +26,810 (+4.39%) | 0.18% | $13 M | Nov 3, 2026 |
| 39 | SEI Investments Co | 636,995 | -53,902 (-7.80%) | 0.18% | $13 M | Nov 10, 2026 |
| 40 | AQR Capital Management LLC | 623,998 | -171,030 (-21.51%) | 0.18% | $13 M | Nov 16, 2026 |
| 41 | Prudential Financial Inc | 620,428 | +289,260 (+87.35%) | 0.18% | $12 M | Nov 16, 2026 |
| 42 | Jpmorgan Chase & Co | 617,276 | -177,724 (-22.36%) | 0.18% | $12 M | Nov 12, 2026 |
| 43 | D. E. Shaw & Co., Inc. | 568,653 | -205,402 (-26.54%) | 0.16% | $11 M | Nov 16, 2026 |
| 44 | Tucker Asset Management LLC | 511,064 | -500,000 (-49.45%) | 0.15% | $10 M | Oct 29, 2026 |
| 45 | Woodline Partners LP | 482,264 | New | 0.14% | $10 M | Nov 16, 2026 |
| 46 | Voleon Capital Management LP | 464,452 | -21,600 (-4.44%) | 0.13% | $9 M | Nov 16, 2026 |
| 47 | Amundi | 440,347 | +400,457 (+1003.90%) | 0.13% | $9 M | Nov 6, 2026 |
| 48 | Quartz Partners, LLC | 433,074 | -23,017 (-5.05%) | 0.12% | $9 M | Nov 3, 2026 |
| 49 | Exchange Traded Concepts, LLC | 430,557 | +64,467 (+17.61%) | 0.12% | $9 M | Oct 28, 2026 |
| 50 | Envestnet Asset Management Inc | 429,089 | +32,135 (+8.10%) | 0.12% | $9 M | Nov 16, 2026 |
| 51 | Public Employees Retirement Association Of Colorado | 426,516 | +106,700 (+33.36%) | 0.12% | $9 M | Nov 12, 2026 |
| 52 | Alliancebernstein L.P. | 419,926 | -13,300 (-3.07%) | 0.12% | $8 M | Nov 16, 2026 |
| 53 | Hillsdale Investment Management Inc. | 418,679 | -230,500 (-35.51%) | 0.12% | $8 M | Nov 12, 2026 |
| 54 | Rhumbline Advisers | 403,210 | -1,533 (-0.38%) | 0.12% | $8 M | Nov 10, 2026 |
| 55 | Legal & General Group Plc | 402,424 | +6,779 (+1.71%) | 0.12% | $8 M | Nov 16, 2026 |
| 56 | RPg Family Wealth Advisory, LLC | 401,494 | -352,686 (-46.76%) | 0.12% | $8 M | Nov 12, 2026 |
| 57 | Victory Capital Management Inc | 399,353 | -122,535 (-23.48%) | 0.11% | $8 M | Nov 10, 2026 |
| 58 | Franklin Templeton Inc | 352,793 | -45,396 (-11.40%) | 0.10% | $7 M | Nov 12, 2026 |
| 59 | Informed Momentum Co LLC | 341,465 | +3,802 (+1.13%) | 0.10% | $7 M | Nov 16, 2026 |
| 60 | Credit Agricole S A | 328,300 | +114,013 (+53.21%) | 0.09% | $7 M | Nov 13, 2026 |
| 61 | Swiss National Bank | 306,700 | -13,300 (-4.16%) | 0.09% | $6 M | Nov 12, 2026 |
| 62 | Millennium Management LLC | 294,727 | +279,966 (+1896.66%) | 0.08% | $6 M | Nov 16, 2026 |
| 63 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 286,022 | +51,249 (+21.83%) | 0.08% | $6 M | Nov 16, 2026 |
| 64 | Osaic Holdings, Inc. | 275,228 | +140,608 (+104.45%) | 0.08% | $6 M | Nov 12, 2026 |
| 65 | HRT Financial LP | 273,633 | New | 0.08% | $6 M | Nov 13, 2026 |
| 66 | Danske Bank A/s | 271,291 | New | 0.08% | $5 M | Nov 9, 2026 |
| 67 | Healthcare Of Ontario Pension Plan Trust Fund | 246,781 | -26,056 (-9.55%) | 0.07% | $5 M | Nov 13, 2026 |
| 68 | Mariner, LLC | 245,906 | -67,819 (-21.62%) | 0.07% | $5 M | Nov 12, 2026 |
| 69 | Russell Investments Group, Ltd. | 232,670 | -117,759 (-33.60%) | 0.07% | $5 M | Nov 6, 2026 |
| 70 | Signature Wealth Management Partners, LLC | 232,426 | New | 0.07% | $5 M | Oct 21, 2026 |
| 71 | ExodusPoint Capital Management, LP | 232,171 | -24,672 (-9.61%) | 0.07% | $5 M | Nov 16, 2026 |
| 72 | Price T Rowe Associates Inc /MD/ | 227,433 | -3,564 (-1.54%) | 0.07% | $5 M | Nov 16, 2026 |
| 73 | Stifel Financial Corp | 224,857 | +11,260 (+5.27%) | 0.06% | $5 M | Nov 12, 2026 |
| 74 | Segall Bryant & Hamill, LLC | 223,019 | -17,041 (-7.10%) | 0.06% | $4 M | Nov 16, 2026 |
| 75 | Martingale Asset Management L P | 222,931 | -60,102 (-21.23%) | 0.06% | $4 M | Nov 12, 2026 |
| 76 | Odyssean, LLC | 213,239 | +29,732 (+16.20%) | 0.06% | $4 M | Nov 16, 2026 |
| 77 | NFJ Investment Group, LLC | 201,685 | -16,609 (-7.61%) | 0.06% | $4 M | Nov 9, 2026 |
| 78 | Quantinno Capital Management LP | 201,561 | -7,469 (-3.57%) | 0.06% | $4 M | Nov 13, 2026 |
| 79 | Paralel Advisors LLC | 187,941 | +2,110 (+1.14%) | 0.05% | $4 M | Nov 10, 2026 |
| 80 | Natixis Advisors, LLC | 187,734 | +60,068 (+47.05%) | 0.05% | $4 M | Nov 13, 2026 |
| 81 | Wilshire Advisors LLC | 187,361 | New | 0.05% | $4 M | Nov 12, 2026 |
| 82 | Artemis Investment Management LLP | 186,125 | 0 (0.00%) | 0.05% | $4 M | Oct 8, 2026 |
| 83 | Citigroup Inc | 183,161 | -31,882 (-14.83%) | 0.05% | $4 M | Nov 4, 2026 |
| 84 | California State Teachers Retirement System | 179,821 | -22,841 (-11.27%) | 0.05% | $4 M | Nov 13, 2026 |
| 85 | Two Sigma Investments, LP | 175,170 | -58,100 (-24.91%) | 0.05% | $4 M | Nov 16, 2026 |
| 86 | Zacks Investment Management | 172,369 | New | 0.05% | $3 M | Nov 16, 2026 |
| 87 | Virtus Wealth Solutions LLC | 159,140 | New | 0.05% | $3 M | Nov 3, 2026 |
| 88 | State Of Wisconsin Investment Board | 158,908 | +36,922 (+30.27%) | 0.05% | $3 M | Nov 16, 2026 |
| 89 | VANGUARD ASSET MANAGEMENT, Ltd | 156,754 | +41,570 (+36.09%) | 0.04% | $3 M | Nov 13, 2026 |
| 90 | State Board Of Administration Of Florida Retirement System | 155,270 | -51,526 (-24.92%) | 0.04% | $3 M | Nov 13, 2026 |
| 91 | Nomura Asset Management Co LTD | 152,602 | +98,624 (+182.71%) | 0.04% | $3 M | Nov 12, 2026 |
| 92 | Globeflex Capital L P | 152,428 | +5,920 (+4.04%) | 0.04% | $3 M | Nov 16, 2026 |
| 93 | Deutsche Bank AG\ | 148,506 | -22,982 (-13.40%) | 0.04% | $3 M | Nov 6, 2026 |
| 94 | Jones Financial Companies Lllp | 148,022 | +37,543 (+33.98%) | 0.04% | $3 M | Nov 13, 2026 |
| 95 | Corient Private Wealth LP | 146,470 | -4,228 (-2.81%) | 0.04% | $3 M | Nov 16, 2026 |
| 96 | CANADA LIFE ASSURANCE Co | 143,704 | +2,926 (+2.08%) | 0.04% | $3 M | Nov 13, 2026 |
| 97 | O'shaughnessy Asset Management, LLC | 141,490 | -3,215 (-2.22%) | 0.04% | $3 M | Nov 12, 2026 |
| 98 | Barclays PLC | 131,485 | +21,122 (+19.14%) | 0.04% | $3 M | Nov 6, 2026 |
| 99 | Y-Intercept (Hong Kong) Ltd | 130,358 | +42,215 (+47.89%) | 0.04% | $3 M | Oct 16, 2026 |
| 100 | Empowered Funds, LLC | 117,478 | New | 0.03% | $2 M | Nov 13, 2026 |
Mutual funds holding Amneal Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Core S&P Small-Cap ETFBlackRock Fund Advisors | 10.38 M | $180 M | 3.0% | 0.16% | +1.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.56 M | $96 M | 1.6% | <0.01% | +0.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 4.38 M | $76 M | 1.3% | 0.09% | +19% | Jun 30, 2026 |
| 🇺🇸 Vanguard Small-Cap Index FundThe Vanguard Group, Inc. | 4.03 M | $70 M | 1.2% | 0.04% | +1.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Small-Cap Value Index FundThe Vanguard Group, Inc. | 2.55 M | $44 M | 0.73% | 0.07% | +0.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.97 M | $34 M | 0.57% | 0.03% | +4.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.86 M | $34 M | 0.53% | 0.10% | +26% | Jul 31, 2026 |
| 🇺🇸 Invesco S&P SmallCap Momentum ETFInvesco Capital Management LLC | 1.84 M | $34 M | 0.53% | 1.1% | +25% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio S&P 600 Small Cap ETFSSGA Funds Management, Inc. | 1.59 M | $27 M | 0.45% | 0.16% | +3.3% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 1.24 M | $23 M | 0.35% | 0.11% | +0.4% | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 1.20 M | $21 M | 0.34% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.19 M | $21 M | 0.34% | 0.14% | +545% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 1.07 M | $20 M | 0.31% | 0.13% | +3.9% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 1.00 M | $18 M | 0.29% | 0.23% | +0.1% | Jul 31, 2026 |
| 🇺🇸 Invesco Pharmaceuticals ETFInvesco Capital Management LLC | 965,545 | $18 M | 0.28% | 3.7% | +45% | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 880,942 | $16 M | 0.25% | 0.07% | no change | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 880,150 | $16 M | 0.25% | 0.40% | −1.9% | Jul 31, 2026 |
| 🇺🇸 iShares S&P Small-Cap 600 Growth ETFBlackRock Fund Advisors | 927,710 | $16 M | 0.27% | 0.20% | +5.6% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value and Inflection FundColumbia Management Investment Advisers, LLC | 979,518 | $13 M | 0.28% | 1.5% | +3.9% | May 31, 2026 |
| 🇺🇸 Vanguard Tax-Managed Small-Cap FundThe Vanguard Group, Inc. | 722,603 | $13 M | 0.21% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Neuberger Intrinsic Value FundNeuberger Berman Investment Advisers LLC | 940,108 | $12 M | 0.27% | 0.82% | −0.1% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 684,817 | $12 M | 0.20% | 0.20% | +4.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 875,635 | $12 M | 0.25% | 0.03% | −2.5% | May 31, 2026 |
| 🇺🇸 Applied Finance Explorer FundApplied Finance Advisors, LLC | 606,953 | $11 M | 0.17% | 1.1% | no change | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small/Mid Cap Equity FundTeachers Advisors, LLC | 590,790 | $11 M | 0.17% | 0.40% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 819,083 | $11 M | 0.24% | 0.05% | −0.5% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc. | 607,932 | $11 M | 0.17% | 0.09% | +207% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S & P 600 Small Cap Growth ETFSSGA Funds Management, Inc. | 596,295 | $10 M | 0.17% | 0.20% | +11% | Jun 30, 2026 |
| 🇺🇸 iShares S&P Small-Cap 600 Value ETFBlackRock Fund Advisors | 593,327 | $10 M | 0.17% | 0.13% | −10% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 772,909 | $10 M | 0.22% | 0.06% | +3.7% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 498,837 | $9 M | 0.14% | 0.28% | +12% | Jun 30, 2026 |
| 🇺🇸 VictoryShares US Small Mid Cap Value Momentum ETFVictory Capital Management Inc. | 496,929 | $9 M | 0.14% | 0.49% | +14% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 453,710 | $8 M | 0.13% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors | 448,079 | $8 M | 0.13% | 0.68% | −5.6% | Jun 30, 2026 |
| 🇺🇸 Vanguard S&P Small-Cap 600 Index FundThe Vanguard Group, Inc. | 587,289 | $8 M | 0.17% | 0.13% | +0.8% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 414,058 | $8 M | 0.12% | 0.10% | +25% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc. | 426,750 | $7 M | 0.12% | 1.7% | −8.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 396,443 | $7 M | 0.11% | 0.04% | −63% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 353,284 | $6 M | 0.10% | 0.16% | +9.5% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S & P 600 Small Cap Value ETFSSGA Funds Management, Inc. | 365,082 | $6 M | 0.10% | 0.13% | +3.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 475,933 | $6 M | 0.14% | 0.03% | +1.1% | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 327,358 | $6 M | 0.09% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Allspring Opportunity FundAllspring Funds Management, LLC | 337,273 | $6 M | 0.10% | 0.31% | −1.8% | Jun 30, 2026 |
| 🇺🇸 Congress SMid Growth ETFCongress Asset Management Company | 310,580 | $6 M | 0.09% | 1.3% | new | Jul 31, 2026 |
| 🇺🇸 First Trust Mid Cap Core AlphaDEX FundFirst Trust Advisors L.P. | 297,521 | $5 M | 0.09% | 0.40% | +1.6% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 312,418 | $5 M | 0.09% | 0.09% | +26% | Jun 30, 2026 |
| 🇺🇸 First Trust Mid Cap Growth AlphaDEX FundFirst Trust Advisors L.P. | 265,125 | $5 M | 0.08% | 0.84% | +20% | Jul 31, 2026 |
| 🇺🇸 JNL Small Cap Index FundJackson National Asset Management, LLC | 269,365 | $5 M | 0.08% | 0.16% | +2.6% | Jun 30, 2026 |
| 🇺🇸 Schwab Fundamental U.S. Small Company ETFCharles Schwab Investment Management, Inc. | 329,065 | $4 M | 0.09% | 0.05% | −18% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 246,891 | $4 M | 0.07% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 232,604 | $4 M | 0.07% | 0.42% | +13% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 315,959 | $4 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 226,583 | $4 M | 0.07% | 0.10% | +27% | Jul 31, 2026 |
| 🇺🇸 Convergence Long/Short Equity ETFConvergence Investment Partners, LLC. | 305,100 | $4 M | 0.09% | 0.65% | +115% | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 209,911 | $4 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Virtus NFJ Small-Cap Value FundVirtus Investment Advisers, LLC | 201,102 | $3 M | 0.06% | 1.3% | new | Jun 30, 2026 |
| 🇺🇸 Invesco S&P SmallCap 600 Revenue ETFInvesco Capital Management LLC | 264,304 | $3 M | 0.08% | 0.19% | new | May 31, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 199,963 | $3 M | 0.06% | 0.40% | −2.9% | Jun 30, 2026 |
| 🇺🇸 SRH U.S. Quality GARP ETFParalel Advisors LLC | 187,941 | $3 M | 0.05% | 1.6% | +1.1% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 257,697 | $3 M | 0.07% | <0.01% | +3.5% | May 31, 2026 |
| 🇺🇸 Allspring Common Stock FundAllspring Funds Management, LLC | 195,798 | $3 M | 0.06% | 0.50% | +39% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 256,310 | $3 M | 0.07% | 0.18% | +0.3% | May 31, 2026 |
| 🇺🇸 Columbia Small Cap Index FundColumbia Management Investment Advisers, LLC | 253,406 | $3 M | 0.07% | 0.13% | −6.2% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 180,824 | $3 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 180,457 | $3 M | 0.05% | 0.25% | +25% | Jul 31, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc. | 186,484 | $3 M | 0.05% | 1.3% | no change | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 185,243 | $3 M | 0.05% | 0.19% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 185,187 | $3 M | 0.05% | 0.08% | +18% | Jun 30, 2026 |
| 🇺🇸 Putnam Small Cap Value FundPutnam Investment Management, LLC | 239,600 | $3 M | 0.07% | 1.1% | +4.9% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 167,953 | $3 M | 0.05% | 0.11% | −14% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 177,638 | $3 M | 0.05% | 0.14% | +683% | Jun 30, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 226,564 | $3 M | 0.07% | 0.71% | −24% | May 31, 2026 |
| 🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC | 161,781 | $3 M | 0.05% | 0.14% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc. | 160,931 | $3 M | 0.05% | 0.45% | −41% | Jul 31, 2026 |
| 🇺🇸 Allspring SMID Core ETFAllspring Funds Management, LLC | 165,979 | $3 M | 0.05% | 2.4% | — | Jun 30, 2026 |
| 🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC | 155,101 | $3 M | 0.04% | 0.12% | +7.6% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Growth PortfolioDimensional Fund Advisors LP | 145,122 | $3 M | 0.04% | 0.13% | −5.9% | Jul 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright Healthcare Momentum ETFInvesco Capital Management LLC | 143,351 | $3 M | 0.04% | 1.1% | new | Jul 31, 2026 |
| 🇺🇸 PSF Small-Cap Stock Index PortfolioPGIM INVESTMENTS LLC | 146,750 | $3 M | 0.04% | 0.16% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 188,463 | $2 M | 0.05% | <0.01% | +4.0% | May 31, 2026 |
| 🇺🇸 SmallCap S&P 600 Index FundPrincipal Global Investors, LLC | 126,926 | $2 M | 0.04% | 0.17% | −4.9% | Jul 31, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc. | 133,744 | $2 M | 0.04% | 1.2% | +9.6% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC | 166,555 | $2 M | 0.05% | 0.19% | +81% | May 29, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 124,301 | $2 M | 0.04% | 0.19% | −6.7% | Jun 30, 2026 |
| 🇺🇸 SEI Select Small Cap ETFSEI INVESTMENTS MANAGEMENT CORPORATION | 120,630 | $2 M | 0.03% | 0.36% | +9.1% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 120,602 | $2 M | 0.03% | 0.09% | +19% | Jun 30, 2026 |
| 🇺🇸 Empower S&P Small Cap 600 Index FundEmpower Capital Management, LLC | 120,458 | $2 M | 0.03% | 0.16% | no change | Jun 30, 2026 |
| 🇺🇸 SIMT Small Cap Growth FundSEI Institutional Managed Trust | 116,343 | $2 M | 0.03% | 0.64% | −7.1% | Jun 30, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 115,552 | $2 M | 0.03% | 0.39% | −3.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard S&P Small-Cap 600 Value Index FundThe Vanguard Group, Inc. | 149,030 | $2 M | 0.04% | 0.10% | −0.2% | May 31, 2026 |
| 🇺🇸 Thrivent Small Cap Index PortfolioThrivent Financial for Lutherans | 113,125 | $2 M | 0.03% | 0.16% | −0.2% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 105,437 | $2 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Value FundBridgeway Capital Management, LLC | 106,449 | $2 M | 0.03% | 0.54% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 135,550 | $2 M | 0.04% | 0.18% | −1.5% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 100,542 | $2 M | 0.03% | 0.25% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 100,235 | $2 M | 0.03% | 0.26% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 94,028 | $2 M | 0.03% | <0.01% | +5.6% | Jul 31, 2026 |
| 🇺🇸 Small Company FundAmerican Century Investment Management, Inc. | 95,773 | $2 M | 0.03% | 0.85% | +33% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 93,914 | $2 M | 0.03% | <0.01% | −5.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 123,308 | $2 M | 0.04% | 0.10% | +2.5% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Amneal Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | J. Kevin BuchiDirector | Gift | -20,445 | — | — | 75,077 | Form 4 |
| filed | J. Kevin BuchiDirector | Option exercise | +20,445 | $14.45 | $295 K | 95,522 | Form 4 |
| filed | Andrew S. BoyerExecutive Vice President | Gift | -80,000 | — | — | 193,646 | Form 4 |
| filed | Andrew S. BoyerExecutive Vice President | Gift | -152,426 | — | — | 273,646 | Form 4 |
| filed | John KielyDirector | Sell | -50,000 | $17.64 | $882 K | 210,252 | Form 4 |
| filed | John KielyDirector | Gift | -10,000 | — | — | 200,252 | Form 4 |
| filed | Nikita ShahExecutive Vice President | Sell | -146,403 | $17.51 | $2.6 M | 253,390 | Form 4 |
| filed | Jason B. DalyEVP, Chief Legal Officer | Sell | -210,000 | $17.40 | $3.7 M | 35,171 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Ownership and subsidiaries
- AMNEAL PHARMACEUTICALS LLC🇺🇸 WILMINGTON
Markets and events: Amneal Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 14,634 shares at $19.25
- : 160 shares at $18.08
- : 90,162 shares at $17.44
- : 294 shares at $17.99
- : 191 shares at $17.66
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Amneal Pharmaceuticals, Inc. scorecard#
Passes 14 of the 21 checks that could be worked out: strongest in growth (6 of 6), weakest in valuation (1 of 6). Fiscal year 2025; market cap of Oct 16, 2026.
Valuation1 of 6
- ✗P/E below its peers' median50.3×P/E 50.3× against Pharmaceutical's median of 39.4×.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%4.0%Free cash flow is 4.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yield2.0%Earnings yield 2.0% against the 10-year Treasury's 5.15% on 2026-11-13.
- ✗The price assumes slower growth than the last three years'14.9%The price assumes 14.9% a year for ten years; revenue grew 10.9% a year over the last three.
Growth6 of 6
- ✓Revenue grew in the newest year8.1%Revenue up 8.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years10.9%10.9% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median10.9%10.9% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✓Earnings per share grew in the newest year0.22 vs -0.38Diluted EPS 0.22 in fiscal 2025 against -0.38 the year before (report's currency).
- ✓Net income higher than five years earlier$72 M$72 M in fiscal 2025 against $68 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$72 MNet income $72 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median13.1%13.1% against Pharmaceutical's median of 1.8% (74 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- ✓Return on invested capital above 10%16.5%16.5% in fiscal 2025.
- ✓Operating margin wider than three years earlier13.1%13.1% in fiscal 2025 against -4.3% in 2022.
Financial health3 of 3
- ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.17 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone2.38Z-score 2.38 (grey zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year5.1%Diluted shares up 5.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Amneal Pharmaceuticals, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 13.1% | 1.8% | |
| Net margin | 2.4% | -1.5% | |
| Revenue growth, 3 years a year | 10.9% | 2.5% | |
| Revenue growth | 8.1% | 7.3% | |
| Free cash flow margin | 8.9% | 6.0% |
7of 9on the Piotroski tests of financial strength
- The share count rose 5.1% in the year.
- Shareholders' equity is negative: -$71 million.
- Revenue has grown 6 years in a row.
- Free cash flow has been positive 6 years in a row.
Amneal Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 3,019+8.0%100% | 2,794+16.7%100% | 2,394+8.2%100% | 2,212+5.7%100% | 2,094+5.1%100% | 1,993+22.5%100% | 1,626−2.2%100% | 1,663+60.9%100% | 1,034+1.5%100% | 1,018—100% | |
| Cost of revenue | 1,905+7.4%63.1% | 1,774+12.7%63.5% | 1,573+10.2%65.7% | 1,428r1,416+7.8%64.5% | 1,325r1,302−0.4%63.3% | 1,330+15.9%66.7% | 1,147+22.2%70.5% | 939r947+85.0%56.5% | 507+20.6%49.1% | 421—41.3% | |
| Gross profit | 1,113+9.1%36.9% | 1,020+24.4%36.5% | 821+4.6%34.3% | 785+2.0%35.5% | 769+22.4%36.7% | 628+78.0%31.5% | 353−50.7%21.7% | 716+36.2%43.1% | 526−11.9%50.9% | 597—58.7% | |
| Research and development | 186−2.4%6.2% | 191+16.3%6.8% | 164−16.2%6.8% | 196−3.1%8.8% | 202+12.2%9.6% | 180−4.3%9.0% | 188−3.2%11.6% | 194+13.3%11.7% | 171−4.2%16.6% | 179—17.6% | |
| Selling, general and administrative | 527+10.6%17.5% | 476+10.9%17.1% | 430+7.5%18.0% | 400+9.4%18.1% | 366+11.9%17.5% | 327+12.8%16.4% | 290+27.1%17.8% | 228r230+109%13.7% | 109−8.2%10.5% | 119—11.7% | |
| Operating income | 394+58.1%13.1% | 249+22.0%8.9% | 204—8.5% | −95−162%−4.3% | 153+67.5%7.3% | 91—4.6% | −249—−15.3% | −20−108%−1.2% | 245−14.0%23.7% | 285—28.0% | |
| Other non-operating income (expense) | −255—−8.4% | −304—−10.9% | −245—−10.2% | −153—−6.9% | −121—−5.8% | −127−546%−6.4% | 28—1.7% | −183—−11.0% | −74—−7.1% | −70—−6.9% | |
| Income before tax | 139—4.6% | −55—−2.0% | −40—−1.7% | −248−891%−11.2% | 31—1.5% | −36—−1.8% | −220—−13.5% | −203−218%−12.2% | 171−20.2%16.6% | 215—21.1% | |
| Income tax | 11−40.2%0.4% | 19+123%0.7% | 8.5+26.9%0.4% | 6.7−40.5%0.3% | 11—0.5% | −104−127%−5.2% | 383—23.6% | −1.4−171%−0.1% | 2.0−63.0%0.2% | 5.4—0.5% | |
| Net income including minority interests | 128—4.2% | −74—−2.6% | −49—−2.0% | −255−1363%−11.5% | 20−70.6%1.0% | 69—3.4% | −604—−37.1% | −201−219%−12.1% | 169−19.1%16.4% | 209—20.6% | |
| Minority interests' share of net income | 56+29.9%1.9% | 43+21.9%1.5% | 35—1.5% | −125−1412%−5.7% | 9.5—0.5% | −22—−1.1% | −242—−14.9% | −33−2053%−2.0% | 1.7−18.1%0.2% | 2.0—0.2% | |
| Net income attributable to shareholders | 72—2.4% | −117—−4.2% | −84r−79—−3.5% | −271−2156%−12.2% | 13−80.6%0.6% | 68r91—3.4% | −604r−362—−37.1% | −20—−1.2% | 0—0.0% | 0—0.0% | |
| Earnings per share, basic | 0.23—— | -0.38—— | -0.48—— | -0.86−1329%— | 0.07−88.7%— | 0.62—— | -2.74—— | -0.16—— | — | — | |
| Earnings per share, diluted | 0.22—— | -0.38—— | -0.48—— | -0.86−1329%— | 0.07−88.5%— | 0.61—— | -2.74—— | -0.16—— | — | — | |
| Shares, weighted average (basic) | 313+1.4%— | 309+75.4%— | 176+16.7%— | 151+1.4%— | 149+1.0%— | 147+11.6%— | 132+3.8%— | 127—— | — | — | |
| Shares, weighted average (diluted) | 325+5.1%— | 309+75.4%— | 176+16.7%— | 151−0.6%— | 152+2.0%— | 149+12.7%— | 132+3.8%— | 127—— | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 282+155%7.7% | 111+20.8%3.2% | 92r92+252%2.6% | 26−89.5%0.7% | 248−27.4%6.3% | 341+126%8.5% | 151−29.1%4.1% | 213+188%4.9% | 74r0+171%5.5% | 27—— | |
| Receivables | — | — | — | 742+12.0%19.5% | 663+3.7%16.8% | 639+5.7%15.9% | 604+25.5%16.5% | 481+37.0%11.1% | 351—26.2% | — | |
| Inventory | 606−1.0%16.5% | 612+5.3%17.5% | 581+9.5%16.7% | 531+8.4%14.0% | 489−0.3%12.4% | 491+28.8%12.2% | 381−16.7%10.4% | 457+61.0%10.5% | 284—21.2% | — | |
| Other current assets | 98+21.9%2.7% | 81−2.4%2.3% | 83−20.2%2.4% | 104−6.0%2.7% | 110+50.0%2.8% | 73+4.7%1.8% | 70−45.3%1.9% | 128+203%2.9% | 42—3.2% | — | |
| Current assets | 1,911+20.4%52.0% | 1,588+15.2%45.3% | 1,378−2.4%39.7% | 1,412−7.1%37.2% | 1,520−2.0%38.6% | 1,552+28.2%38.7% | 1,210−5.9%33.0% | 1,287+66.7%29.6% | 772r0—57.5% | — | |
| Property, plant and equipment | 443+4.2%12.0% | 425−5.1%12.1% | 448−4.7%12.9% | 470−8.6%12.4% | 514+7.6%13.1% | 478−0.1%11.9% | 478−12.2%13.0% | 544+11.8%12.5% | 487—36.3% | — | |
| Right-of-use (leased) assets | 54+27.6%1.5% | 42−2.2%1.2% | 43−22.9%1.2% | 56−7.0%1.5% | 60+2.8%1.5% | 59−15.9%1.5% | 70—1.9% | — | — | — | |
| Goodwill | 595−0.3%16.2% | 597−0.2%17.1% | 599−0.0%17.2% | 599+1.0%15.8% | 593+13.4%15.1% | 523+24.6%13.1% | 420−1.6%11.4% | 426+1512%9.8% | 26−7.0%2.0% | 28—— | |
| Other intangible assets | 563−23.1%15.3% | 732−17.7%20.9% | 890−18.8%25.6% | 1,096−6.1%28.8% | 1,167−10.6%29.6% | 1,305−5.7%32.6% | 1,383−16.4%37.7% | 1,655+3611%38.0% | 45—3.3% | — | |
| Total assets | 3,678+5.1%100% | 3,501+0.8%100% | 3,473−8.6%100% | 3,799−3.6%100% | 3,940−1.7%100% | 4,006+9.3%100% | 3,666−15.8%100% | 4,353+224%100% | 1,342r0—100% | — | |
| Accounts payable | — | 259+80.2%7.4% | 144−13.5%4.1% | 166+26.6%4.4% | 131r131−14.4%3.3% | 153r153+48.6%3.8% | 103r103−10.3%2.8% | 115r115+64.0%2.6% | 70—5.2% | — | |
| Debt due within a year | 6.8−97.0%0.2% | 224+557%6.4% | 34+13.9%1.0% | 30−2.1%0.8% | 31−30.8%0.8% | 44+106%1.1% | 21+0.1%0.6% | 21−75.9%0.5% | 89r89—6.6% | — | |
| Current liabilities | 882−22.0%24.0% | 1,130+33.4%32.3% | 847+12.5%24.4% | 753+11.2%19.8% | 677+0.1%17.2% | 677+23.0%16.9% | 550−0.6%15.0% | 554+86.6%12.7% | 297r0—22.1% | — | |
| Long-term debt | 2,565+18.7%69.7% | 2,162−9.4%61.7% | 2,386−7.9%68.7% | 2,592−3.3%68.2% | 2,680−2.0%68.0% | 2,735+4.8%68.3% | 2,609−0.8%71.2% | 2,631+94.1%60.4% | 1,355r1,355—101% | — | |
| Non-current liabilities | 2,791+15.5%75.9% | 2,416−5.8%69.0% | 2,565−9.6%73.9% | 2,838−1.4%74.7% | 2,879−3.2%73.1% | 2,972+7.4%74.2% | 2,769−4.6%75.5% | 2,903+104%66.7% | 1,421—106% | — | |
| Total liabilities | — | — | — | — | — | — | — | — | 0—0.0% | — | |
| Retained earnings | −535—−14.5% | −607—−17.3% | −490—−14.1% | −406—−10.7% | −276—−7.0% | −287—−7.2% | −378—−10.3% | −21—−0.5% | −383—−28.5% | — | |
| Shareholders' equity | −71—−1.9% | −109−652%−3.1% | 20−93.4%0.6% | 298−17.2%7.9% | 360+18.8%9.1% | 303+30.7%7.6% | 232−54.0%6.3% | 505—11.6% | 0—0.0% | — | |
| Minority interests | −0.5—−0.0% | −0.2−207%−0.0% | 0.2—0.0% | −114−1825%−3.0% | 6.6−84.1%0.2% | 42−63.7%1.0% | 115−70.7%3.1% | 392—9.0% | — | — | |
| Total equity | −71—−1.9% | −110−647%−3.1% | 20−89.1%0.6% | 184−49.9%4.8% | 367+6.4%9.3% | 345−0.5%8.6% | 347−61.3%9.5% | 896—20.6% | 0—0.0% | — | |
| Total liabilities and equity | 3,678+5.1%100% | 3,501+0.8%100% | 3,473−8.6%100% | 3,799−3.6%100% | 3,940−1.7%100% | 4,006+9.3%100% | 3,666−15.8%100% | 4,353+224%100% | 1,342r0—100% | — | |
| Shares outstanding | — | — | — | — | — | — | — | — | 0.0—— | — | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 32+15.1%1.1% | 28+3.5%1.0% | 27−15.8%1.1% | 32+12.1%1.4% | 28+36.9%1.4% | 21−4.3%1.0% | 22−87.1%1.3% | 168—10.1% | 0—0.0% | 0—0.0% | |
| Cash from operating activities | 340+15.2%11.3% | 295−14.6%10.6% | 346+431%14.4% | 65−73.1%2.9% | 242−36.2%11.6% | 379+22129%19.0% | 1.7−99.3%0.1% | 250+6.9%15.0% | 234+104%22.7% | 115—11.3% | |
| Capital expenditure | −70—−2.3% | −52—−1.9% | −43—−1.8% | −46—−2.1% | −48—−2.3% | −56—−2.8% | −47—−2.9% | −83—−5.0% | −95—−9.2% | −123—−12.1% | |
| Intangible assets bought | −16—−0.5% | −15—−0.5% | −22—−0.9% | −42—−1.9% | −1.7—−0.1% | −4.4—−0.2% | −50—−3.1% | −14—−0.8% | −20—−1.9% | −1.9—−0.2% | |
| Acquisitions, net of cash acquired | — | 0—0.0% | 0—0.0% | −85—−3.8% | −147—−7.0% | −251—−12.6% | 0—0.0% | −325—−19.5% | 0—0.0% | 0—0.0% | |
| Cash from investing activities | −112—−3.7% | −63—−2.3% | −69—−2.9% | −174—−7.9% | −194—−9.3% | −318—−15.9% | −20—−1.2% | −396—−23.8% | −99—−9.5% | −125—−12.2% | |
| Debt issued | 2,695—89.3% | 0−100%0.0% | 218—9.1% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Dividends paid | — | — | — | — | — | 0—0.0% | 0—0.0% | −183—−11.0% | −375—−36.3% | −201—−19.7% | |
| Cash from financing activities | −32—−1.0% | −212—−7.6% | −213—−8.9% | −107—−4.8% | −138−205%−6.6% | 132—6.6% | −46−116%−2.8% | 288—17.3% | −95—−9.2% | −19—−1.9% | |
| Exchange-rate effect on cash | −1.7—−0.1% | −1.0−1637%−0.0% | 0.1—0.0% | −5.7−5672%−0.3% | 0.1−90.2%0.0% | 1.0—0.1% | −2.2—−0.1% | −0.7—−0.0% | −0.2−116%−0.0% | 1.5—0.1% | |
| Change in cash | 195+907%6.4% | 19−69.8%0.7% | 64—2.7% | −222—−10.0% | −90−147%−4.3% | 194—9.8% | −66−147%−4.1% | 141+249%8.5% | 40—3.9% | −28—−2.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 3,196+8.9%100% | 863+10.0%100% | 796+9.9%100% | 723+3.9%100% | 814*+11.5%100% | 785+11.7%100% | 725+3.2%100% | 695+5.5%100% | 731*+18.4%100% | 702—100% | 702—100% | 659—100% | 617*—100% | |
| Cost of revenue | 1,910+2.9%59.8% | 529+3.5%61.3% | 462+5.3%58.0% | 402−8.4%55.7% | 517*+10.6%63.5% | 511+17.9%65.1% | 438−3.0%60.5% | 440+4.4%63.2% | 468*+9.5%64.0% | 433—61.6% | 452—64.4% | 421—63.9% | 427*—69.2% | |
| Gross profit | 1,286+19.2%40.2% | 334+22.0%38.7% | 335+16.9%42.0% | 320+25.1%44.3% | 297*+13.1%36.5% | 274+1.6%34.9% | 286+14.5%39.5% | 256+7.5%36.8% | 263*+38.5%36.0% | 270—38.4% | 250—35.6% | 238—36.1% | 190*—30.8% | |
| Research and development | 181−12.2%5.7% | 68+7.9%7.9% | 39−18.7%4.9% | 38−4.1%5.3% | 35*−35.8%4.3% | 63+3.7%8.1% | 48+33.0%6.6% | 40+1.9%5.8% | 54*+17.7%7.4% | 61—8.7% | 36—5.1% | 39—6.0% | 46*—7.5% | |
| Selling, general and administrative | 574+12.7%18.0% | 140+1.3%16.2% | 149+19.7%18.7% | 139+17.4%19.2% | 146*+13.8%18.0% | 138+16.1%17.6% | 124+6.7%17.2% | 118+5.1%17.0% | 129*+18.1%17.6% | 119—16.9% | 116—16.6% | 113—17.1% | 109*—17.7% | |
| Operating income | 479+33.8%15.0% | 95+35.6%11.1% | 130+16.5%16.3% | 142+41.3%19.6% | 112*+47.8%13.8% | 70−20.8%9.0% | 111+16.7%15.4% | 100—14.4% | 76*+434%10.4% | 89—12.6% | 95—13.6% | −11—−1.6% | 14*—2.3% | |
| Other non-operating income (expense) | −258—−8.1% | −80—−9.3% | −59—−7.4% | −62—−8.5% | −57*—−7.0% | −76—−9.6% | −60—−8.2% | −63—−9.0% | −91*—−12.5% | −73—−10.4% | −75—−10.7% | −65—−9.8% | −98*—−15.8% | |
| Income before tax | 221+223%6.9% | 15—1.7% | 71+37.3%8.9% | 80+114%11.1% | 55*—6.8% | −5.2−134%−0.7% | 52+153%7.1% | 37—5.4% | −15*—−2.1% | 15—2.2% | 20—2.9% | −76—−11.5% | −83*—−13.5% | |
| Income tax | 12+8.4%0.4% | 2.8—0.3% | 1.4−91.5%0.2% | 2.2−83.1%0.3% | 5.7*+4.4%0.7% | −23−737%−3.0% | 16+345%2.2% | 13+109%1.9% | 5.4*−45.1%0.7% | 3.7—0.5% | 3.6—0.5% | 6.2—0.9% | 9.9*—1.6% | |
| Net income including minority interests | 209+264%6.6% | 12−32.1%1.4% | 70+95.5%8.7% | 78+217%10.8% | 50*—6.1% | 18+54.2%2.3% | 36+112%4.9% | 25—3.5% | −21*—−2.8% | 12—1.7% | 17—2.4% | −82—−12.4% | −93*—−15.1% | |
| Minority interests' share of net income | 62+19.8%1.9% | 20+25.4%2.3% | 12−9.4%1.5% | 16+26.7%2.2% | 14*+40.2%1.8% | 16+32.3%2.0% | 13+22.2%1.8% | 12+24.7%1.8% | 10*+94.9%1.4% | 12—1.7% | 11—1.5% | 10.0—1.5% | 5.3*—0.9% | |
| Net income attributable to shareholders | 133+2159%4.2% | −22−1016%−2.5% | 58+157%7.2% | 62+411%8.6% | 35*—4.3% | 2.4—0.3% | 22+274%3.1% | 12—1.8% | −31*—−4.3% | −0.2—−0.0% | 6.0—0.9% | −92—−13.9% | −99r−101*—−16.0% | |
| Earnings per share, basic | — | -0.06−700%— | 0.18+157%— | 0.20+400%— | — | 0.01—— | 0.07+250%— | 0.04—— | — | 0.00—— | 0.02—— | -0.30—— | — | |
| Earnings per share, diluted | — | -0.06−700%— | 0.18+157%— | 0.19+375%— | — | 0.01—— | 0.07+250%— | 0.04—— | — | 0.00—— | 0.02—— | -0.30—— | — | |
| Shares, weighted average (basic) | 336+6.9%— | 336+6.9%— | 319+1.7%— | 316+1.6%— | — | 314+1.5%— | 314+1.5%— | 311+1.2%— | — | 310—— | 309—— | 307—— | — | |
| Shares, weighted average (diluted) | 336+3.4%— | 336+3.4%— | 328+1.8%— | 329+1.5%— | — | 325+4.9%— | 322+1.1%— | 324+5.4%— | — | 310—— | 319—— | 307—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 157—3.0% | 157−21.8%3.0% | 128+78.4%3.4% | 198+234%5.6% | 282+155%7.7% | 201+172%5.6% | 72+63.5%2.1% | 59+27.2%1.8% | 111+20.8%3.2% | 74—2.1% | 44—1.2% | 47—1.3% | 92r92—2.6% | |
| Inventory | 708—13.4% | 708+15.2%13.4% | 678+11.3%18.0% | 642+6.7%18.1% | 606−1.0%16.5% | 615+3.0%17.1% | 609+5.8%17.8% | 601+5.4%17.9% | 612+5.3%17.5% | 596—17.2% | 576—16.4% | 571—16.5% | 581—16.7% | |
| Other current assets | 197—3.7% | 197+93.8%3.7% | 112+31.3%3.0% | 103+16.5%2.9% | 98+21.9%2.7% | 102+23.9%2.8% | 85+4.5%2.5% | 89+1.4%2.6% | 81−2.4%2.3% | 82—2.4% | 82—2.3% | 87—2.5% | 83—2.4% | |
| Current assets | 2,095—39.8% | 2,095+14.0%39.8% | 1,947+22.9%51.6% | 1,798+19.0%50.8% | 1,911+20.4%52.0% | 1,838+21.5%51.1% | 1,585+6.7%46.3% | 1,510+9.4%44.9% | 1,588+15.2%45.3% | 1,513—43.7% | 1,485—42.3% | 1,380—39.9% | 1,378—39.7% | |
| Property, plant and equipment | 573—10.9% | 573+31.6%10.9% | 457+3.8%12.1% | 445+4.1%12.6% | 443+4.2%12.0% | 435+0.9%12.1% | 440+3.5%12.9% | 427−2.9%12.7% | 425−5.1%12.1% | 431—12.5% | 425—12.1% | 440—12.7% | 448—12.9% | |
| Right-of-use (leased) assets | — | — | — | — | 54+27.6%1.5% | — | — | — | 42−2.2%1.2% | — | — | — | 43—1.2% | |
| Goodwill | 772—14.7% | 772+29.6%14.7% | 593−0.7%15.7% | 594−0.6%16.8% | 595−0.3%16.2% | 596−0.4%16.6% | 597−0.2%17.5% | 597−0.2%17.8% | 597−0.2%17.1% | 598—17.3% | 599—17.1% | 599—17.3% | 599—17.2% | |
| Other intangible assets | 1,551—29.5% | 1,551+164%29.5% | 588−9.5%15.6% | 535−22.4%15.1% | 563−23.1%15.3% | 588−24.6%16.3% | 650−20.8%19.0% | 689−19.8%20.5% | 732−17.7%20.9% | 780—22.5% | 820—23.4% | 859—24.9% | 890—25.6% | |
| Total assets | 5,267—100% | 5,267+46.3%100% | 3,776+10.3%100% | 3,540+5.2%100% | 3,678+5.1%100% | 3,600+4.0%100% | 3,423−2.5%100% | 3,365−2.6%100% | 3,501+0.8%100% | 3,461—100% | 3,510—100% | 3,456—100% | 3,473—100% | |
| Accounts payable | — | — | — | — | — | 266+13.3%7.4% | 206+3.1%6.0% | 193+9.8%5.7% | 259+80.2%7.4% | 235—6.8% | 200—5.7% | 175—5.1% | 144—4.1% | |
| Debt due within a year | 24—0.5% | 24+232%0.5% | 6.0−80.9%0.2% | 6.2−80.5%0.2% | 6.8−97.0%0.2% | 7.2−96.8%0.2% | 31−86.2%0.9% | 32−5.6%0.9% | 224+557%6.4% | 225—6.5% | 225—6.4% | 34—1.0% | 34—1.0% | |
| Current liabilities | 1,120—21.3% | 1,120+29.9%21.3% | 883−20.2%23.4% | 728−32.3%20.6% | 882−22.0%24.0% | 862−21.3%23.9% | 1,107−0.6%32.3% | 1,076+28.9%32.0% | 1,130+33.4%32.3% | 1,095—31.6% | 1,114—31.7% | 834—24.1% | 847—24.4% | |
| Long-term debt | 2,916—55.4% | 2,916+13.6%55.4% | 2,564+19.5%67.9% | 2,566+19.1%72.5% | 2,565+18.7%69.7% | 2,567+18.3%71.3% | 2,146−1.4%62.7% | 2,154−9.4%64.0% | 2,162−9.4%61.7% | 2,170—62.7% | 2,178—62.0% | 2,378—68.8% | 2,386—68.7% | |
| Non-current liabilities | 3,507—66.6% | 3,507+26.1%66.6% | 2,776+17.5%73.5% | 2,772+18.0%78.3% | 2,791+15.5%75.9% | 2,780+15.9%77.2% | 2,362−1.6%69.0% | 2,349−11.0%69.8% | 2,416−5.8%69.0% | 2,399—69.3% | 2,400—68.4% | 2,639—76.3% | 2,565—73.9% | |
| Retained earnings | −437—−8.3% | −437—−8.3% | −415—−11.0% | −473—−13.4% | −535—−14.5% | −570—−15.8% | −572—−16.7% | −595—−17.7% | −607—−17.3% | −576—−16.6% | −576—−16.4% | −582—−16.8% | −490—−14.1% | |
| Shareholders' equity | 531—10.1% | 531—10.1% | 33—0.9% | −45—−1.3% | −71—−1.9% | −109—−3.0% | −112—−3.3% | −132—−3.9% | −109−652%−3.1% | −93—−2.7% | −57—−1.6% | −64—−1.8% | 20—0.6% | |
| Minority interests | 0—0.0% | 0—0.0% | 0—0.0% | −0.6—−0.0% | −0.5—−0.0% | −0.5—−0.0% | −0.4—−0.0% | −0.3−451%−0.0% | −0.2−207%−0.0% | −0.1—−0.0% | −0.0—−0.0% | 0.1—0.0% | 0.2—0.0% | |
| Total equity | 531—10.1% | 531—10.1% | 33—0.9% | −46—−1.3% | −71—−1.9% | −110—−3.1% | −113—−3.3% | −132—−3.9% | −110−647%−3.1% | −94—−2.7% | −57—−1.6% | −64—−1.8% | 20—0.6% | |
| Total liabilities and equity | 5,267—100% | 5,267+46.3%100% | 3,776+10.3%100% | 3,540+5.2%100% | 3,678+5.1%100% | 3,600+4.0%100% | 3,423−2.5%100% | 3,365−2.6%100% | 3,501+0.8%100% | 3,461—100% | 3,510—100% | 3,456—100% | 3,473—100% | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 38+22.5%1.2% | 11*+27.9%1.2% | 10*+25.6%1.3% | 8.8+21.5%1.2% | 8.2*+13.8%1.0% | 8.2*+15.6%1.0% | 8.3*+23.1%1.1% | 7.3+8.0%1.0% | 7.2*+20.7%1.0% | 7.1*—1.0% | 6.7*—1.0% | 6.7—1.0% | 6.0*—1.0% | |
| Cash from operating activities | 181−44.9%5.7% | 98*−17.0%11.4% | −21*−125%−2.7% | −27−461%−3.7% | 130*+10.4%16.0% | 118*−16.5%15.1% | 84*+111%11.6% | 7.4—1.1% | 118*−13.1%16.2% | 142*—20.2% | 40*—5.7% | −4.4—−0.7% | 136*—22.0% | |
| Capital expenditure | −92—−2.9% | −32*—−3.7% | −31*—−3.9% | −8.2—−1.1% | −22*—−2.7% | −12*—−1.6% | −23*—−3.2% | −13—−1.9% | −15*—−2.1% | −17*—−2.4% | −11*—−1.5% | −9.2—−1.4% | −9.9*—−1.6% | |
| Intangible assets bought | −100—−3.1% | −12*—−1.3% | −77*—−9.7% | −7.9—−1.1% | −3.0*—−0.4% | −7.4*—−0.9% | −0.9*—−0.1% | −4.2—−0.6% | −0.6*—−0.1% | −3.6*—−0.5% | −0.8*—−0.1% | −9.7—−1.5% | −20*—−3.2% | |
| Cash from investing activities | −662—−20.7% | −472*—−54.7% | −123*—−15.4% | −22—−3.0% | −45*—−5.6% | −22*—−2.9% | −27*—−3.7% | −18—−2.6% | −16*—−2.2% | −21*—−2.9% | −6.5*—−0.9% | −20—−3.0% | −32*—−5.1% | |
| Debt issued | 530—16.6% | 395*−85.3%45.8% | 0*—0.0% | 135—18.6% | 0*—0.0% | 2,695*—343% | 0*—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from financing activities | 425—13.3% | 415*+598%48.1% | 79*—10.0% | −59—−8.2% | −10*—−1.2% | 59*—7.6% | −42*—−5.8% | −39—−5.6% | −61*—−8.4% | −92*—−13.1% | −35*—−5.0% | −23—−3.5% | −101*—−16.3% | |
| Exchange-rate effect on cash | −2.0—−0.1% | −0.6*—−0.1% | −0.2*—−0.0% | −1.0—−0.1% | −0.2*—−0.0% | −0.7*−10014%−0.1% | −0.3*—−0.0% | −0.5—−0.1% | −0.7*−468%−0.1% | 0.0*—0.0% | −0.1*—−0.0% | −0.2—−0.0% | 0.2*—0.0% | |
| Change in cash | −58−136%−1.8% | 41*−73.7%4.7% | −65*−524%−8.1% | −109—−15.0% | 75*+86.0%9.2% | 155*+439%19.7% | 15*—2.1% | −50—−7.2% | 40*+1045%5.5% | 29*—4.1% | −2.0*—−0.3% | −47—−7.2% | 3.5*—0.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Amneal Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Subtotal dosage forms$1.7 B57%+3.4%
- Oral solid$726 M24%+5.4%
- Subtotal therapeutic classes$528 M17%+20%
- Distribution$408 M14%-5.9%
- Central nervous system$333 M11%+19%
- Government$270 M8.9%+69%
- Other dosage forms$252 M8.4%+25%
- Auto-injector$233 M7.7%+11%
- Transdermal$188 M6.2%+3.6%
- Injectable$161 M5.3%-2.5%
- Hormonal / allergy$155 M5.1%+19%
- Biosimilar$100 M3.3%-20%
- Oral liquid$73 M2.4%-30%
- Other therapeutic classes$40 M1.3%+39%
- Institutional$35 M1.2%-17%
- Other$31 M1.0%+17%
- International$12 M0.4%+35%
- License agreement$1 M0.0%-92%
Business segments
- Affordable Medicines$1.7 B58%+3.6%
- AvKARE$745 M25%+12%
- Specialty$529 M18%+19%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Amneal Pharmaceuticals, Inc. operates: 8 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 32 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters3 offices18 subsidiaries | — |
| 🇮🇳 India | 6 subsidiaries | — |
| 🇮🇪 Ireland | 3 subsidiaries | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇲🇽 Mexico | 1 subsidiary | — |
| 🇸🇬 Singapore | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Amneal Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chintu Patel, Chirag Patel | $8.7 M | $24.4 M | $3.0 M | $276 (peers $156) |
| 2024Chintu Patel, Chirag Patel | $7.2 M | $11.9 M | $2.6 M | $173 (peers $118) |
| 2023Chirag Patel, Chintu Patel | $2.4 M | $9.5 M | $1.7 M | $133 (peers $109) |
| 2022Chintu Patel, Chirag Patel | $5.1 M | −$1.8 M | $2.3 M | $44 (peers $108) |
| 2021Chintu Patel, Chirag Patel | $4.8 M | $1.4 M | $2.4 M | $105 (peers $113) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Amneal Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 5 · New debt 3 · Unregistered share sale 2 · Shareholder vote 4 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Acquisition or sale completedMaterial agreementNew debtUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Material agreementNew debt | 8-K | |
| Directors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K/A | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 3, 2026
Lobbying by Amneal Pharmaceuticals, Inc.#
$1.8 M spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and manufacturing.
- Health Issues8 reports
- Manufacturing4 reports
Lobbying firms hired in 2025
Tarplin, Downs & Young, LLC $240 K · OGR $80 K
The firms' fees are part of Amneal Pharmaceuticals, Inc.'s own reported expenses, so they are not added again.
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $590 K | $590 K | 9 |
| 2025 | $1.8 M | $1.8 M | 12 |
| 2024 | $1.5 M | $1.5 M | 8 |
| 2023 | $290 K | — | 4 |
| 2022 | $200 K | — | 5 |
| 2021 | $380 K | — | 8 |
| 2020 | $170 K | — | 3 |
| 2019 | $20 K | — | 1 |
| 2018 | $100 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Amneal Pharmaceuticals”, “Amneal Pharmaceutical” and “AMNEAL PHARMACEUTICALS”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Amneal Pharmaceuticals, Inc.#
37 labor condition applications certified in fiscal 2026 for 37 positions, at a median wage of $113 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Scientist, Quality ControlChemists | 4 | $97 K |
| Associate Process EngineerIndustrial Engineers | 2 | $82 K |
| Lead Scientist, Quality ControlChemists | 2 | $113 K |
| Sr. Scientist, Analytical R&DChemists | 2 | $103 K |
| AI EngineerComputer Occupations, All Other | 1 | $79 K |
| Associate Director, Manufacturing OperationsIndustrial Production Managers | 1 | $173 K |
| Associate Director, R&D Program MgmtChemists | 1 | $189 K |
| Associate Manager, Quality ControlChemists | 1 | $116 K |
| Associate Validation EngineerIndustrial Engineers | 1 | $81 K |
| Director, Commercial AnalyticsFinancial Quantitative Analysts | 1 | $220 K |
Where: Piscataway, NJ 29 · Branchburg, NJ 5 · Bridgewater, NJ 3
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 37 | 37 | $113 K | 39 |
| FY2025 | 25 | 25 | $105 K | 25 |
| FY2024 | 32 | 32 | $104 K | 34 |
| FY2023 | 33 | 33 | $105 K | 33 |
| FY2022 | 31 | 32 | $96 K | 33 |
| FY2021 | 41 | 41 | $95 K | 42 |
| FY2020 | 32 | 34 | $92 K | 34 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as AMNEAL PHARMACEUTICALS LLC
FDA drug approvals: Amneal Pharmaceuticals, Inc.#
519 approved applications held, 2 of them new molecular entities; 12 approvals and 0 new uses in 2026.
| Approved | Drug | Kind |
|---|---|---|
| 2026-11-02 | CyclophosphamideCyclophosphamide · ANDA210890 | Generic drug (ANDA) |
| 2026-10-15 | Sodium PhosphatesSodium Phosphate, Dibasic, Heptahydrate, Sodium Phosphate, Monobasic, Monohydrate · ANDA218274 | Generic drug (ANDA) |
| 2026-09-18 | Lanreotide AcetateLanreotide Acetate · ANDA218217 | Generic drug (ANDA) |
| 2026-07-09 | Sodium BicarbonateSodium Bicarbonate · NDA220790 | New drug (NDA) |
| 2026-06-08 | MacitentanMacitentan · ANDA211000 | Generic drug (ANDA) |
| 2026-06-02 | RomidepsinRomidepsin · ANDA219099 | Generic drug (ANDA) |
| 2026-06-01 | PhytonadionePhytonadione · ANDA217734 | Generic drug (ANDA) |
| 2026-05-14 | TretinoinTretinoin · ANDA217497 | Generic drug (ANDA) |
| 2026-01-28 | Sertraline HydrochlorideSertraline Hydrochloride · ANDA219655 | Generic drug (ANDA) |
| 2026-01-26 | Cupric ChlorideCupric Chloride · ANDA217287 | Generic drug (ANDA) |
| 2026-01-14 | Eltrombopag OlamineEltrombopag Olamine · ANDA212884 | Generic drug (ANDA) |
| 2026-01-13 | Sodium BicarbonateSodium Bicarbonate · ANDA217523 | Generic drug (ANDA) |
| 2025-12-31 | Ketamine HydrochlorideKetamine Hydrochloride · ANDA220380 | Generic drug (ANDA) |
| 2025-12-19 | BoncresaDenosumab-Mobz · BLA761456 | Biologic (BLA) |
| 2025-12-19 | OziltusDenosumab-Mobz · BLA761457 | Biologic (BLA) |
| 2025-12-12 | DeflazacortDeflazacort · ANDA217173 | Generic drug (ANDA) |
| 2025-12-08 | EpinephrineEpinephrine · ANDA218208 | Generic drug (ANDA) |
| 2025-11-28 | CyclosporineCyclosporine · ANDA211909 | Generic drug (ANDA) |
| 2025-11-13 | IohexolIohexol · ANDA217737 | Generic drug (ANDA) |
| 2025-11-04 | PhytonadionePhytonadione · ANDA216601 | Generic drug (ANDA) |
| 2025-10-29 | Neomycin And Polymyxin B Sulfates And HydrocortisoneHydrocortisone, Neomycin Sulfate, Polymyxin B Sulfate · ANDA217803 | Generic drug (ANDA) |
| 2025-10-14 | EpinephrineEpinephrine · ANDA217485 | Generic drug (ANDA) |
| 2025-10-02 | Labetalol HydrochlorideLabetalol Hydrochloride · ANDA218870 | Generic drug (ANDA) |
| 2025-09-30 | Neomycin And Polymyxin B Sulfates And HydrocortisoneHydrocortisone, Neomycin Sulfate, Polymyxin B Sulfate · ANDA217735 | Generic drug (ANDA) |
| 2025-09-26 | Calcitonin-SalmonCalcitonin Salmon · ANDA216294 | Generic drug (ANDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (AMNEAL, AMNEAL PHARMS and IMPAX LABS), so they follow acquisitions
Product recalls by Amneal Pharmaceuticals, Inc.#
16 recalls since 2015, 248,710 units in the notices that give a number. Drugs (FDA): 16.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.Defective Container; packets were found to be either empty or partially full.DrugsClass II | 2,592 | D-0873-2026 | |
| Primidone Tablets, USP, 50 mg, 100 Tablets per Bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC: 53746-544-01Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.DrugsClass III | 27,936 | D-0585-2026 | |
| traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382220, India, Distributed by: Amneal Pharmaceuticals LLC, Glasgow, KY 42141, NDC 60219-2348-5.Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).DrugsClass II | 29,542 | D-0408-2026 | |
| Magnesium Sulfate in Water for Injection, 4g/100 mL (40mg/mL) IV bag, further packaged in cartons of 12 x 100 mL IV bags, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad, 382110, India, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1720-3.Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.DrugsClass I | 784 | D-0478-2026 | |
| chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, 100-count bottles Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA; Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 69238-1062-1. (and 4 more products)Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.DrugsClass II | 3,363 | D-0619-2025 | |
| Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg, Rx Only, a) 100 Tablets per Bottle, NDC: 65162-271-10, b) 500 Tablets per Bottle, NDC: 65162-271-50, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad, 382213, INDIA, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807.Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.DrugsClass I | 6,396 | D-0488-2025 | |
| Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box)Presence of Particulate MatterDrugsClass I | 62 | D-0402-2025 | |
| Methotrexate Tablets, USP, 2.5mg, 100-count Bottle, RX Only, Distributed By: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC# 69238-1423-1Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.DrugsClass III | 12,624 | D-0629-2024 | |
| Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25). (and 4 more products)CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIDrugsClass II | — | D-0613-2020 | |
| Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10- Capsules Each (30 Capsules)-. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC 69238-1174-3Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits.DrugsClass III | 2,460 | D-0321-2020 | |
| Benazepril HCl Tablets, USP 40 mg, 100 count bottles, Rx only, Distributed by Amneal Pharmaceuticals, Bridgewater, NJ NDC 65162-754-10Presence of Foreign Tablet/Capsule; Promethazine HCl tablet found in the Benazepril HCl bottleDrugsClass III | 9,720 | D-0134-2020 | |
| Methylergonovine Maleate USP 0.2 mg Tablets a) 12 count (NDC 69238-1605-02) and b) 28 count bottles (NDC 69238-1605-08)Presence of Foreign Tablet/Capsule; one Promethazine tablet was found in a bottle of Methylergonovine Maleate tabletsDrugsClass III | 2,256 | D-1516-2019 | |
| Fosphenytoin Sodium Injection, USP 500 mg PE*/10 mL, Made in India. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807, NDC 70121-1390-1Presence of particulate matterDrugsClass II | 12,584 | D-0610-2018 | |
| Esterified Estrogens & Methyltestosterone Tablets, USP 1.25 mg/2.5 mg, 100-count bottles, Rx Only, Manufactured by: Ammeal Pharmaceuticals of NY Hauppauge, NY 11788 Distributed by: Seton Pharmaceuticals Manasquan, NJ 08736, NDC 13925-172-01 (and 1 more products)Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.DrugsClass III | 19,176 | D-1439-2019 | |
| Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL. 10 mL Single Dose Vial, Rx Only. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807. NDC: 70121-1390-7Presence of Particulate MatterDrugsClass II | 14,000 | D-0076-2018 | |
| Rabeprazole Sodium Delayed Release Tablets, 20 mg, a) 30-count bottle (NDC 65162-0724-03), b) 90-count bottle (NDC 65162-0724-09), Rx Only, Manufactured by Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad INDIA 382220, Distributed by Amneal Pharmaceuticals, Bridgewater, NJ 08807Failed Dissolution SpecificationsDrugsClass II | 105,215 | D-0693-2017 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2018 | · | · | · | · | 550 | · | · | · | · | · | · | · | 550 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 550 people | Restructuring planSEC 8-K | “The Company currently expects the facility closures to reduce its workforce by approximately 550 positions.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Amneal Pharmaceuticals, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 3 November 2026automatic update · Nov 3, 2026
Amneal Pharmaceuticals, Inc. announced results on 3 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $863 million (up 10% from a year earlier) and a net loss of $22 million.
- Mutual funds: 246 funds hold $1.2 billionautomatic update · Jul 31, 2026
246 mutual funds in 2 countries hold shares of Amneal Pharmaceuticals, Inc. worth $1.2 billion, about 21.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 125 funds added shares and 75 sold; on balance they bought $67 million. Share splits are not counted as trading.
How Amneal Pharmaceuticals, Inc. compares in Pharmaceutical
- Market cap$6.7 B · higher than 86% of 393
- Revenue$3.0 B · higher than 82% of 324
- Net margin4.2% · higher than 38% of 313
- Revenue growth8.1% · higher than 53% of 107
- P/E ratio50.3× · lower than 20% of 172
- Price / sales2.1× · lower than 56% of 219
- FCF yield4.0% · higher than 56% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc.🇺🇸 | $6.7 B | 50.3× | 4.2% | +8.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 16, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Amneal Pharmaceuticals, Inc.? Verify and update this profile — free
Show Amneal Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.